摘要
目的探讨CA-125在肺部疾病中的临床应用价值。方法采用化学发光免疫分析法测定健康对照者和肺部良恶性疾病患者的血清CA-125水平,对合并胸腔积液者,同时测定胸水中的CA-125水平,进行统计分析。结果各疾病组的CA-125与正常对照组比较均有显著增高(P<0.05),有胸水组的胸水CA-125阳性率均达100%。胸水中CA-125值均显著高于血清CA-125值(P<0.01)。在无胸水的情况下,恶性疾病的血清CA-125值明显高于良性疾病(P<0.05);但在合并胸腔积液时,恶性疾病与良性疾病的血清CA-125值之间无显著差异(P>0.05),而胸水中的CA-125值则有非常显著差异(P<0.01)。结论CA-125对肺部良恶性疾病的鉴别诊断有一定的价值,特别是胸水中的CA-125水平,可以作为监测病情及判断疗效的有效指标。
To probe the clinical application of CA-125 in the lung diseases. Methods Using the chemiluminescence immunoassay to assay the CA-125 levels in serum healthy among humen and different kinds of clinically diagnosed patients with lung diseases. When patients had pleural fluids, the levels of CA-125 in pleural effusion were determined at the same time. The statistical analysis based on these results was carried out. Results The CA-125 levels in patients were markedly higher than that in healthy samples （P〈0.05）. The positive rates of CA-125 levels in pleural effusion among patients with hy- drothorax were 100%. The CA-125 levels in pleural effusion were higher than those in serum（P〈0.01）. Without hydrothorax, the CA-125 level in serum among patients with malignant lung diseases was higher than that of benign diseases（P〈0.05）. But if with hydrothorax, the CA-125 in serum were not significant between benign and malignant diseases（P〉0.05）. To the contrast, the CA-125 levels in pleural effusion between these two kinds of diseases were more significant（P〈0. 01）. Conclusion Measurement of CA-125 level, especially the level in pleural effusion, not only provide useful information for distinctive diagnosis of different kinds of lung diseases, but also is a good target in evaluation of disease extent and effect of treatments in patients with different kinds of lung diseases.
出处
《空军总医院学报》
2007年第1期13-15,共3页
Journal of General Hospital of Air Force,PLA
